Why clinical biomarkers face a slow climb before regulators accept them as surrogate endpoints
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
What Madrigal Pharmaceuticals, Inc.’s siRNA deal signals for the future of MASH treatment
Can Madrigal Pharmaceuticals, Inc. reshape MASH treatment with ARO-PNPLA3? Discover what this precision strategy means for the future.
How Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with the Phase 2 DGAT-2 inhibitor ervogastat
Find out how Madrigal Pharmaceuticals is building a multi-mechanism MASH pipeline with ervogastat, a Phase 2 oral DGAT-2 inhibitor.